Integrated Advisors Network LLC Has $3.94 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Integrated Advisors Network LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 17.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 27,231 shares of the company's stock after selling 5,566 shares during the quarter. Integrated Advisors Network LLC's holdings in Johnson & Johnson were worth $3,938,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $32,000. Conquis Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth $36,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.31 during trading hours on Tuesday, hitting $153.25. 6,979,932 shares of the stock were exchanged, compared to its average volume of 7,961,247. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $368.73 billion, a PE ratio of 23.05, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company's fifty day simple moving average is $155.05 and its two-hundred day simple moving average is $153.65. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.39%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Raymond James dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.